Myungin eye listing on KOSPI in 2009

Published: 2008-09-23 06:41:00

Updated: 2008-09-23 06:41:00

Myungin Pharm says the firm is filing an application with the Korea Exchange (KRX), the operator of the KOSPI and Kosdaq, for a review of its listing in the first half of next year.

The Financial Supervisory Commission said that the firm should meet all prerequisites, such as financial soundne...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK